SABCS 2024
Interviews and expert commentary from SABCS 2024 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer
SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base
28 March 2025
7:56
Audio Journal of Oncology
E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS
SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can
16 January 2025
13:47
Audio Journal of Oncology
AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer
SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr
11 January 2025
15:27